Nuclear medicine treatments of well-differentiated neuroendocrine tumors (NETs) are gaining increasing acceptance among clinicians. Peptide receptor radionuclide therapy (PRRT) is an effective systemic treatment, providing a significant survival benefit and improving patients' quality of life. Locoregional selective internal radiation therapy (SIRT) is a safe and effective treatment for unresectable NET liver metastases, providing good local tumor control and symptomatic relief. Few reports in literature examine the sequential use of PRRT and SIRT in metastatic NET. We report the case of a metastatic NET patient treated with sequential PRRT-SIRT achieving a long disease control interval without cumulative toxicity issues.
From the *Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan
†Nuclear Medicine Unit, Policlinico “Umberto I”, Sapienza University of Rome
§Gastrointestinal Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Received for publication May 9, 2018; revision accepted December 24, 2018.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Giulia Anna Follacchio, MD, Nuclear Medicine Unit, Department of Radiology, Oncology and Human Pathology, Policlinico MD, “Umberto I”, Sapienza University, 324, Viale Regina Elena, 00161, Rome, Italy. E-mail: firstname.lastname@example.org.